Table 2.
Baseline Characteristics of Study Population
| Characteristic | SSI-plus-routine-medications group (n = 75) | Routine-medications-only group (n = 78) | P value |
| Age, mean (SD), y | 62.5 (13.4) | 65.9 (14.2) | .61 |
| Male sex, No. (%) | 28 (37.3) | 25 (32.1) | .49 |
| Race, No. (%) | .64 | ||
| White, not of Hispanic Origin | 39 (52.0) | 44 (56.4) | |
| Black, not of Hispanic Origin | 27 (36.0) | 29 (37.2) | |
| American Indian/Alaska Native | 3 (4.0) | 1 (1.3) | |
| Hispanic | 6 (8.0) | 4 (5.1) | |
| Admission blood glucose, mean (SD), mg/dL* | 202.9 +/− 82.7 | 186.4 +/− 89.6 | .49 |
| Co-morbidities, No. (%) | .81 | ||
| Cardiovascular | 143 (44.1) | 152 (44.1) | |
| Pulmonary | 35 (10.8) | 21 (6.1) | |
| Infectious | 30 (9.3) | 39 (11.3) | |
| Neurological | 24 (7.4) | 27 (7.8) | |
| Gastrointestinal | 15 (4.6) | 21 (6.1) | |
| Endocrine | 15 (4.6) | 16 (4.6) | |
| Rheumatological | 12 (3.7) | 10 (2.9) | |
| Psychiatric | 10 (3.1) | 13 (3.8) | |
| Oncology | 8 (2.5) | 10 (2.9) | |
| Renal | 7 (2.2) | 9 (2.6) | |
| Other† | 25 (7.7) | 27 (7.8) | |
| Routine diabetes medications, No. (%) | |||
| Oral sulfonylurea | 47 (62.7) | 37 (47.4) | .06 |
| Biguanide | 21 (28.0) | 20 (25.6) | .74 |
| Thiazolidinedione | 11 (14.7) | 11 (14.1) | .92 |
| Short-acting insulin | 4 (5.3) | 7 (9.0) | .38 |
| Intermediate acting insulin | 25 (33.3) | 39 (50.0) | .04 |
| Combination therapy | 32 (42.7) | 35 (44.9) | .78 |
| Diet controlled | 5 (6.7) | 3 (3.9) | .43 |
* Conversion factor to SI = 0.05551
† Other = hematologic, ophthalmologic, genitourinary, fluid/electrolyte/nutrition, orthopedic, adverse drug event, dermatologic (all < 2%)